Ambroxol HCL represents a premium-grade active pharmaceutical ingredient specifically engineered for respiratory drug formulations, featuring a guaranteed purity range of 99.0% to ...

Ambroxol HCL represents a premium-grade active pharmaceutical ingredient specifically engineered for respiratory drug formulations, featuring a guaranteed purity range of 99.0% to 101.0% that ensures exceptional consistency in pharmaceutical manufacturing. This white, crystalline powder with molecular formula C13H18Br2N2O·HCl and molecular weight of 414.6 g/mol delivers reliable mucolytic and expectorant properties essential for effective respiratory therapeutics. The compound demonstrates optimal solubility profiles in key pharmaceutical solvents including N,N-dimethylformamide and methanol, while maintaining stability through proper light-sensitive storage conditions. This high-purity API meets rigorous quality standards, providing manufacturers with a trusted foundation for developing respiratory medications that deliver predictable clinical outcomes and patient benefits.

The pharmaceutical industry extensively incorporates Ambroxol HCL into respiratory treatment regimens across multiple therapeutic categories, particularly in medications addressing chronic bronchitis, asthma, COPD, and other respiratory disorders. Manufacturers leverage this API's ability to effectively reduce mucus viscosity and enhance pulmonary clearance in various dosage forms including syrups, tablets, capsules, and inhalable solutions. The ingredient's well-established safety profile supports its use across diverse patient demographics, from pediatric formulations to geriatric medications, while its compatibility with numerous excipients enables flexible formulation strategies. Global regulatory compliance ensures seamless integration into manufacturing processes targeting international markets, with documentation supporting pharmacopeial standards across major regulatory regions.

Businesses selecting Ambroxol HCL API benefit from unparalleled reliability and batch-to-batch consistency that minimizes production variability and quality control challenges. This consistency translates to reduced manufacturing risks, faster time-to-market for new products, and enhanced end-product performance that meets evolving patient needs. The API's adherence to international quality standards provides assurance of regulatory compliance, while its chemical stability supports extended shelf life and manufacturing flexibility. By incorporating this high-performance ingredient, pharmaceutical manufacturers gain competitive advantage through superior product efficacy, streamlined production processes, and strengthened market positioning with respiratory therapeutics that demonstrate proven clinical effectiveness.

Key Features:
- Guaranteed purity range between 99.0% and 101.0%
- Molecular structure C13H18Br2N2O·HCl with 414.6 g/mol weight
- White crystalline powder with odorless characteristics
- Optimal solubility in N,N-dimethylformamide and methanol
- Light-protected storage requirements for maximum stability

Benefits:
- Consistent batch-to-batch performance in drug formulations
- Enhanced mucus clearance and bronchial relief properties
- Flexible compatibility with various pharmaceutical excipients
- Reliable stability profile supporting extended product shelf life
- Comprehensive documentation for global regulatory compliance